C4 Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| C4 THERAPEUTICS, INC. | ||
| Date: May 12, 2026 | By: | /s/ Andrew J. Hirsch |
|---|---|---|
| Andrew J. Hirsch | ||
| President and Chief Executive Officer (Principal Executive Officer) | ||
| Date: May 12, 2026 | By: | /s/ Kendra R. Adams |
| Kendra R. Adams | ||
| Chief Financial Officer, Head of Corporate Affairs, and Treasurer (Principal Financial Officer) | ||
| Date: May 12, 2026 | By: | /s/ Mark Mossler |
| Mark Mossler | ||
| Chief Accounting Officer (Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.